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This phase I was study conducted to establish the maximum tolerated dose, dose-limiting toxicity, and recommended dose of
docetaxel in combination with cyclophosphamide as ﬁrst-line chemotherapy for metastatic breast cancer. Twenty-six patients
were treated with cyclophosphamide (600 mg m
72, intravenous bolus) followed by docetaxel (60, 75 or 85 mg m
72, 1-h
intravenous infusion) every 3 weeks. The maximum tolerated dose was docetaxel 85 mg m
72 with cyclophosphamide
600 mg m
72, the dose-limiting toxicity being febrile neutropenia. Grade 4 neutropenia was experienced by all patients, but
was generally brief. Otherwise, the combination was well tolerated with few acute and no chronic non-haematological
toxicities of grade 3/4. Activity was observed at all dose levels and disease sites, and the overall response rate was 42% (95%
conﬁdence interval 22–61%). The pharmacokinetics of docetaxel were not modiﬁed by cyclophosphamide coadministration.
These ﬁndings establish a recommended dose of docetaxel 75 mg m
72 in combination with cyclophosphamide 600 mg m
72
every three weeks for phase II evaluation.
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Docetaxel (Taxotere
TM), a semi-synthetic taxoid, is a relatively new
chemotherapeutic agent with high activity against metastatic breast
cancer. Following ﬁrst-line treatment with docetaxel, objective
response rates of up to 68% have been reported (Chevallier et al,
1995; Dieras et al, 1996; Fumoleau et al, 1996a; Hudis et al,
1996). As second-line treatment for patients with disease resistant
to anthracyclines, currently the most widely administered
chemotherapeutic agents, docetaxel has achieved the highest activ-
ity to date (Ravdin et al, 1995; Valero et al, 1995; Alexopoulos et
al, 1999; Nabholtz et al, 1999; Sjostrom et al, 1999).
Since the use of combination chemotherapy has been associated
with increased response rates compared to single agents (Fossati et
al, 1998), a large programme exploring the feasibility and activity
of docetaxel, in combination with the most active agents in meta-
static breast cancer, was initiated. Several phase I studies were
performed, with combinations including docetaxel and doxorubi-
cin (Misset et al, 1999), docetaxel+doxorubicin+cyclo-
phosphamide (Nabholtz et al, 1997), docetaxel and epidoxorubicin
(Pagani et al, 1999), docetaxel and cisplatin (Crown et al, 1997),
docetaxel and vinorelbine (Fumoleau et al, 1996b), and docetaxel
and 5-ﬂuorouracil (Lortholary et al, 1997).
The programme is also exploring the combination of docetaxel
and cyclophosphamide. The rationale for this combination is based
on the known clinical activity of both docetaxel and cyclophospha-
mide (Rubens et al, 1975) in advanced breast cancer, and results of
preclinical studies in a tumour-bearing mouse model showing
synergy in the therapeutic response to the two drugs (Bissery et al,
1995). In the mouse model, 60% of the highest nontoxic dose of each
agent was administered in combination without additional toxicity.
Considering these clinical and preclinical data, we conducted
this phase I study to explore the feasibility of docetaxel in combi-
nation with cyclophosphamide. The aims of the study were to
determine the maximum tolerated dose, the dose-limiting toxicity,
and the recommended dose for phase II studies of the combination
as ﬁrst-line chemotherapy for metastatic breast cancer. A secondary
objective was to determine the pharmacokinetic proﬁle of docetaxel
in the combination. The starting docetaxel dose of 60 mg m
72 was
selected on the basis of its known antitumour activity and good
safety proﬁle when administered as a single agent (Adachi et al,
1996). The dose of cyclophosphamide was ﬁxed at 600 mg m
72
since this is the effective dose considered active while producing
little toxicity in current protocols.
PATIENTS AND METHODS
Study design and patients
This was a phase I, open-label, non-randomised, dose-ﬁnding
study conducted at two centres (Glasgow, UK; Toulouse, France)
between May 1994 and August 1996.
The study population consisted of women aged between 18 and
75 years with locally advanced or metastatic breast cancer. Histolo-
gical or cytological proof of metastasis was required for patients
with a single metastatic lesion. Further inclusion criteria were
measurable and/or evaluable disease, a WHO performance
status42, normal haematological values (neutrophils52610
9 l
71,
platelets5100610
9 l
71, haemoglobin510 g dl
71), normal renal
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71, creatinine clearance 60 ml
min
71), and normal liver function test (bilirubin41.25 times the
upper limit of the institutional normal value [N]; for the highest
dose level only [docetaxel 100 mg m
72 and cyclophosphamide
600 mg m
72], alanine and aspartate aminotransferases43N, alka-
line phosphatase45N).
Patients were excluded if they had received previous chemother-
apy for metastatic disease. However, prior neoadjuvant and
adjuvant treatments were permitted provided there had been a
chemotherapy-free interval of at least 6 months before study entry.
Hormonal therapies as adjuvant treatment and/or for metastatic
disease (42) were also allowed provided there was a 4-week inter-
val between the last hormonal treatment and study entry in
patients who achieved a response (no time interval was required
for patients with no response). Radiotherapy given at least 4 weeks
previously was permitted except at sites used to assess response in
this study. For all previous antitumour therapies, patients must
have fully recovered from any toxic effects. Patients were ineligible
if they had received previous treatment with docetaxel, paclitaxel,
or colony-stimulating factors.
Further exclusion criteria were pregnancy, lactation, or child-
bearing potential (e.g. not using adequate contraception); a history
of prior malignancies, with the exceptions of non-melanoma skin
cancer and well excised cervical carcinoma in situ; known clinical
brain or leptomeningeal involvement; symptomatic peripheral
neuropathy of grade 52; other serious illnesses and medical condi-
tions; and participation in another clinical study either during the
study or within 30 days of study entry. For the highest dose level
(docetaxel 100 mg m
72 and cyclophosphamide 600 mg m
72),
impaired liver function with alanine and aspartate aminotrans-
ferases 41.5 N associated with alkaline phosphatase 42.5 N was
also an exclusion criterion.
The study was conducted in accordance with the Declaration of
Helsinki, in compliance with local regulations, and with the
approval of an independent Ethics Committee at each centre. All
patients gave written, informed consent to participate in the study.
Treatment plan
Four escalating dose levels of docetaxel and cyclophosphamide
were planned (Table 1). Cyclophosphamide was to be administered
at a ﬁxed dose (600 mg m
72, intravenous bolus) followed by doce-
taxel, without recombinant human granulocyte colony-stimulating
factor (rHuG-CSF) prophylaxis, at increasing doses (60, 75, 85 and
100 mg m
72; 1-h intravenous infusion) every 3 weeks in successive
groups of patients. The order of drug administration was chosen
based on preliminary data from a phase I study examining combi-
nation therapy with paclitaxel (135 mg m
72 starting dose) and
cyclophosphamide (750 mg m
72 ﬁxed dose) (Kennedy et al,
1993). The study explored both cyclophosphamide followed by
paclitaxel and the reverse sequence. The results indicated that
haematological toxicity was sequence-dependent: the median
neutrophil nadir was lower with paclitaxel given ﬁrst (9646
10
6 l
71) than with cyclophosphamide given ﬁrst (1864610
6 l
71).
To avoid hypersensitivity reactions and docetaxel-related skin
toxicity and ﬂuid retention, all patients were given a 3-day corti-
costeroid prophylactic premedication, starting the day before
chemotherapy: oral dexamethasone (20 mg) and ranitidine
(150 mg) were administered 3 and 12 h before docetaxel infusion
and at 0, 12, 24 and 36 h post-infusion, and oral chlorpheniramine
(8 mg) was given at 3 and 12 h before docetaxel infusion.
Treatment was planned for six cycles unless there was evidence
of disease progression, unacceptable toxicity, patient refusal, or no
symptomatic improvement after three cycles. Treatment thereafter
depended on the tumour response during the ﬁrst six cycles.
Patients with an objective response could continue treatment until
disease progression, serious toxicity, or patient refusal occurred.
Patients with stable disease after six cycles or progression at any
time were withdrawn and received salvage treatment at the discre-
tion of the investigator.
Dose levels were assigned at recruitment and no dose escalation
was allowed within the same patient. The protocol stipulated that
at least three patients should be treated at each dose level, with a
1-week interval between entry of the ﬁrst patient and the next
two patients. Before escalating to the next dose level, at least two
patients should have received at least two cycles and have been
observed for acute toxicity for a minimum of 2 weeks. If one
out of the three patients at the same dose level developed dose-
limiting toxicity, three more patients were to be entered at the
same dose level. The maximum tolerated dose was deﬁned as the
dose level at which at least two out of the six patients developed
a dose-limiting toxicity. The recommended dose was deﬁned as
the dose level previous to the maximum tolerated dose. For all
dose levels tested, more than three patients were recruited, in order
to ascertain the safety proﬁle in a larger sample size.
Toxicity was graded according to National Cancer Institute
Common Toxicity Criteria (NCI-CTC) current at the start of the
study. Dose-limiting toxicities were deﬁned as: grade 4 neutropenia
(neutrophil count 50.5610
9 l
71) for 47 days; febrile neutrope-
nia (grade 4 neutropenia concomitant with grade 52 fever);
grade 4 thrombocytopenia (platelet count 525610
9 l
71); grade
3/4 bleeding or infection; grade 4 nausea/vomiting; grade 2 neuro-
logical toxicity; and any other grade 3/4 toxicities, except alopecia
and anaemia. Non-recovery of the neutrophil count (to
51.5610
9 l
71) or platelet count (to 5100610
9 l
71) on day 21
of each cycle were further dose-limiting toxicities.
Dose modiﬁcations were planned for haematological and non-
haematological toxicity. Except for grade 3 neuropathy, for which
patients were withdrawn, in the event of dose-limiting toxicity,
treatment was delayed until recovery to grade 1 then restarted
usually at the dose level below or modiﬁed as appropriate to the
toxicity. If, despite the corticosteroid prophylactic premedication,
a hypersensitivity reaction developed, the symptoms were treated
appropriately, for example with epinephrine for anaphylactic shock
and aminophylline for bronchospasm. No dose modiﬁcation was
planned for localised or peripheral oedema, but the patient could
be withdrawn at the discretion of the investigator. Antiemetic
prophylaxis (metoclopramide or domperidone) could be given
from the ﬁrst cycle onwards, and loperamide to prevent diarrhoea
in subsequent cycles following grade 2/3 diarrhoea; patients with
nausea or diarrhoea despite these measures could be treated with
granisetron or odansetron, but additional treatment with corticos-
teroids was not allowed.
Patient and treatment evaluation
Prestudy evaluations included a medical history and physical exam-
ination, an electrocardiogram, radiology examinations (bilateral
mammography, chest X-ray or CT scan, abdominal ultrasound
or CT scan, bone scan, and instrumental examinations as appropri-
ate for any other measurable and/or evaluable disease), a complete
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Table 1 Planned dose levels of cyclophosphamide and docetaxel, each
given once every 3 weeks
Cyclophosphamide Docetaxel
Dose level (mg m
72) (mg m
72)
I 600 60
II 600 75
III 600 85
IV 600 100
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globin), a biochemistry proﬁle, a baseline toxicity evaluation, and
other investigations as clinically indicated.
Patients were monitored regularly for toxicity, and were asked to
report any clinical adverse events to the investigator. Haematologi-
cal assessments were made twice weekly, or every 2 days in cases of
febrile neutropenia until recovery to grade41 neutropenia and
resolution of all infectious symptoms. Irrespective of the reason
for treatment discontinuation, patients were observed during the
ﬁrst month after the last cycle of treatment in order to monitor
any late adverse events.
Tumour response was assessed according to WHO criteria (Mill-
er et al, 1981). The duration of a partial response dated from the
start of treatment until the ﬁrst documentation of progressive
disease, while the duration of a complete response was from the
time it was ﬁrst documented. The time to ﬁrst response and time
to progression were from the start of study treatment to the ﬁrst
occurrence of response and ﬁrst progression, respectively. Survival
dated from the start of treatment.
Pharmacokinetic analysis
The pharmacokinetics of docetaxel were evaluated during the ﬁrst
cycle only, whereas the pharmacokinetics of cyclophosphamide
were not determined. Blood samples were collected before intrave-
nous infusion of docetaxel, at 30 min after the start of infusion, at
the end of infusion, and at 5, 10, 20, 30, 60, 90 min and 2, 4, 6, 8,
12, 16, 24, 36, 48 and 72 h post-infusion. Plasma docetaxel concen-
trations were measured by high-performance liquid
chromatography, using a C18 reversed-phase column and ultravio-
let detection at 225 nm (Vergniol et al, 1992). The lower
quantiﬁcation limit of this assay was 10 ng ml
71. Pharmacokinetic
parameters were estimated by nonlinear least square regression
analysis using WinNonlin software (Scientiﬁc Consulting Inc,
USA) and a two- or three-compartment open model with ﬁrst-
order elimination.
The following parameters were calculated: the maximum plasma
concentration (Cmax), the area under the plasma concentration-
time curve (AUC[0-?]), total body clearance (CL), the volume
of distribution at steady state (Vss), and the terminal elimination
half-life (t½z).
RESULTS
Patient characteristics
Twenty-six patients with previously untreated metastatic breast
cancer were enrolled into the study (Table 2). The median age
was 56 years and the median WHO performance status was 1.
Eighteen patients (69%) had two or more involved organs; 12
(46%) had visceral involvement, and bone and lymph nodes were
the most frequent disease sites (both 13 patients; 50%). Oestrogen
receptor status was performed in only nine patients; six were ER
negative, three ER positive. Progesterone receptor status was not
assessed in any patient. Thirteen patients (50%) had received
previous adjuvant and/or neoadjuvant chemotherapy, with an
anthracyline-based regimen in six patients (23%). Sixteen patients
had received adjuvant hormonal therapy, 16 as treatment for meta-
static disease, and nine received hormonal therapy both in the
adjuvant and metastatic setting. Nineteen patients (73%) had at
least one bidimensionally measurable lesion, while the remaining
seven patients (27%) had only evaluable disease.
Chemotherapy administration
In total, 144 cycles of chemotherapy were administered during the
study (Table 3). The median number of cycles per patient was six
(range 2–9). At least four cycles were given to 20 patients (77%),
six cycles to 17 patients (65%), and eight cycles to six patients
(23%). The median cumulative doses of docetaxel and cyclopho-
sphamide were 438 mg m
72 (range 149–736 mg m
72) and
3541 mg m
72 (range 1184–5432 mg m
72), respectively. The
median relative dose intensity was 0.98 for each of docetaxel, cyclo-
phosphamide, and the combination.
Most treatment cycles (135; 94%) were administered every 3
weeks as planned. Only nine cycles (6%) were delayed and seven
delays lasted for no longer than 1 week. Dose modiﬁcation was
required for six cycles (4%). Five delays and ﬁve dose modiﬁca-
tions were due to toxicity; the remainder were because of non-
medical reasons.
Safety
All 26 patients were evaluable for safety. Overall, the toxicities seen
at all dose levels were usually haematological and of short duration,
and were rarely severe or non-haematological. Fourteen patients
(54%) discontinued the study after they had completed the
planned six cycles of treatment. Of the 12 patients (46%) who
discontinued treatment earlier, 10 withdrew due to disease progres-
sion; one patient (at the docetaxel 75 mg m
72 dose level)
withdrew due to moderate ﬂuid etention that was observed at cycle
5 and after a cumulative docetaxel dose of 288 mg m
72. One
patient at the docetaxel 60 mg m
72 dose level died secondary to
perforation of the ascending colon complicated by peritonitis.
The patient had been taking non-steroidal anti-inﬂammatory drugs
(NSAIDs) in addition to her corticosteroids, and presented with
haematemesis. She was neutropenic (0.46610
9 l
71) but typhlitis
was not suspected because of the clinical presentation and the
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Table 2 Patient and disease characteristics at baseline
Patient demographics
Characteristic n
a (%)
a
Number of patients 26
Age (years)
median 56
range 42–69
WHO performance status (grade)
median 1
range 0–2
Measurability of disease
bidimensional 19 (73.1%)
evaluable 7 (26.9%)
Number of organs involved
1 8 (30.8%)
2 10 (38.5%)
53 8 (30.8%)
Visceral involvement 12 (46.2%)
Disease sites
bone 13 (50.0%)
lymph node 13 (50.0%)
chest wall 8 (30.8%)
lung 6 (23.1%)
liver 5 (19.2%)
breast 4 (15.4%)
skin 2 (7.7%)
pleural 2 (7.7%)
peritoneum 2 (7.7%)
Prior chemotherapy
total 13 (50.0%)
with anthracyclines 6 (23.1%)
aUnless otherwise stated.
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examination was not carried out.
As expected with these two myelosuppressive drugs, neutropenia
and its complications were the most frequent adverse events (Table
4). Grade 4 neutropenia developed in all patients and its incidence
by cycle was highest at the docetaxel 85 mg m
72 dose level. The
grade 4 neutropenia was, however, generally brief, with a median
duration of 5 to 7 days and a median time to nadir of 7 to 8 days
across the dose levels. At day 22+3, the median neutrophil count
was 54.9610
9 l
71 at all dose levels. Febrile neutropenia was
deﬁned broadly, as grade 4 neutropenia concomitant with grade
52 fever, and occurred in nine patients (35%; 7% of cycles).
The highest incidence was observed at the docetaxel 85 mg m
72
dose level (eight patients). However, at this dose level, only one
patient developed a documented grade 3/4 infection (grade 3 urin-
ary infection at cycle 2).
Although anaemia was noted in all patients (eight grade 1, 14
grade 2, four grade 3), no grade 4 episode occurred. Eight patients
(31%) required a blood transfusion during the study. Thrombocy-
topaenia was uncommon, occurring in four patients (15%), and no
patient experienced a grade 3/4 episode or required a platelet trans-
fusion.
The most common acute non-haematological toxicities consid-
ered to be possibly or probably related to study treatment were
nausea, stomatitis, diarrhoea, and vomiting (Table 5). Episodes
were usually grade 1/2; only a few grade 3/4 episodes were observed
during the study. Alopecia was universal. Asthenia and ﬂuid reten-
tion were frequent (each 50% of patients), but were never severe.
One patient discontinued the study due to moderate ﬂuid reten-
tion. The other docetaxel-related chronic toxicities (i.e. skin
toxicity and nail disorders) were infrequent and never severe.
Maximum tolerated and recommended doses
The maximum tolerated dose of the combination was reached at
the docetaxel 85 mg m
72 dose level. Of the 13 patients treated
at this dose level, six developed dose-limiting toxicity, as a result
of febrile neutropenia (ﬁve patients) or grade three infection
(one patient). The dose-limiting toxicity of the combination was
therefore considered to be febrile neutropenia. The recommended
dose of the combination for phase II evaluation is cyclophospha-
mide 600 mg m
72 administered as an intravenous bolus followed
by docetaxel 75 mg m
72 given as a 1 h intravenous infusion.
Efﬁcacy
Of the 26 patients, only one achieved a complete response and 10 a
partial response, giving an overall response rate of 42% (95%
conﬁdence interval [CI] 22–61%) (Table 6). Objective responses
occurred at all dose levels and disease sites, but were most
common at the docetaxel 85 mg m
72 dose level, with ﬁve partial
responses and one complete response among the 12 evaluable
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Table 3 Treatment administration
Cumulative actual dose (mg m
72)
Relative dose intensity
Dose level Number of cycles
Docetaxel Cyclophosphamide
of combination
n Total Median (range) median (range) median (range) Median (range)
I 6 35 6 (3–8) 359 (180–473) 3573 (1800–4639) 0.98 (0.91–1.00)
II 7 36 5 (2–8) 376 (149–599) 3010 (1201–4764) 0.95 (0.79–1.00)
III 13 73 6 (2–9) 501 (159–736) 3547 (1184–5432) 0.98 (0.64–1.01)
Total 26 144 6 (2–9) 438 (149–736) 3541 (1184–5432) 0.98 (0.64–1.01)
Table 4 Incidence of neutropenia and its related complications
Dose level
I II III Total
Evaluable patients 6 7 13 26
Patients with grade 4 neutropenia 6 (100%) 7 (100%) 13 (100%) 26 (100%)
Evaluable cycles
a 34 36 73 143
Cycles with grade 4 neutropenia 25 (73.5%) 29 (80.6%) 62 (84.9%) 116 (81.1%)
Median duration of grade 4 neutropenia (days) 5 (range:3–11) 7 (range:3–14) 5 (range:2–10) (range:2–14)
Patients with febrile neutropenia 0 (0%) 1 (14.3%) 8 (61.5%) 9 (34.6%)
Patients with grade 3/4 infection 0 (0%) 1 (14.3%) 1 (7.7%) 2 (7.7%)
aOne cycle not evaluable, due to missing complete blood count data.
Table 5 Patients with non-haematological toxicities possibly or probably
related to study treatment (all cycles)
Total
Grade 3/4 (or
severe
b)
Adverse event
a n (%) n (%)
Acute
Nausea 19 (73.1%) 1 (3.8%)
Stomatitis 16 (61.5%) 1 (3.8%)
Diarrhoea 14 (53.8%) 2 (7.7%)
Vomiting 13 (50.0%) 1 (3.8%)
Infection 6 (23.1%) 2 (7.7%)
Allergy 5 (19.2%) 1 (3.8%)
Chronic
Alopecia 24 (92.3%) 0 –
Asthenia
b 13 (50.0%) 0 –
Fluid retention
b 13 (50.0%) 0 –
Neurosensory toxicity 7 (26.9%) 0 –
Skin toxicity 7 (26.9%) 0 –
Pulmonary toxicity 3 (11.5%) 0 –
Weight gain or loss 3 (11.5%) 0 –
Nail disorder
b 3 (11.5%) 0 –
aAdverse events occurring with a frequency of ( 10% are reported.
bNon-NCI-CTC
gradeable adverse events were rated as mild, moderate, or severe.
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85 mg m
72 dose level by a patient with axillary lymph node invol-
vement, but with no visceral or bone involvement. The time to ﬁrst
response ranged from 2.9 to 19.9+ weeks and the duration of
response from 15.0 to 52.3+ weeks. It should be noted that the
response lasted for longer than 25 weeks in eight out of the 10
responding patients. The duration of response was censored in
one-half of responders, due to further radiotherapy (one patient)
and no documentation of progressive disease at the study cut-off
date (four patients).
The median time to disease progression was 25.9 weeks (range
4.1 to 55.1 weeks), and with a median follow-up of 7.9 months,
median survival was 10.8 months (range: 1.6 to 18.4 months).
Pharmacokinetics of docetaxel
The pharmacokinetic proﬁle of docetaxel was evaluated in 20
patients. Marked inter-patient variability was observed especially
for Vss and t½z. However, the Cmax and AUC[0-?] of docetaxel
increased as expected with dose. The CL, Vss, and t½z of docetaxel
were relatively stable over the dose range investigated, with mean
overall values of 22.1 l h m
72,9 3lm
72, and 11.8 h, respectively
(Table 7).
DISCUSSION
A wide range of drugs have been tested in breast cancer, and
historically the agents with the greatest activity are anthracyclines,
alkylating agents, 5-ﬂuorouracil, methotrexate, cyclophosphamide,
and vinca alkaloids (Henderson, 1991; Marty et al, 1992). The
anthracyclines have long since been considered as the most active
agents in the treatment of breast cancer, with reported response
rates ranging from 29% (second-line) to 53% (ﬁrst-line) (Frederik-
sen et al, 1978; Steiner et al, 1983; Jain et al, 1985; Brambilla et al,
1986; Carmo-Pereira et al, 1987; Richards et al, 1992). Combina-
tion regimens are more effective than single-agent chemotherapy,
and currently the highest overall response rate in breast cancer
(up to 60%) is achieved with anthracycline-containing regimens
such as cyclophosphamide, doxorubicin or epirubicin, and 5-ﬂuor-
ouracil (CAF or FEC) (Mouridsen, 1992; Harris et al, 1993).
Doxorubicin is the most widely administered anthracycline.
However, continued administration of this agent is limited by an
increased risk of cardiotoxicity, and a cumulative dose not exceed-
ing 450–550 mg m
72 is recommended (Von Hoff et al, 1979).
Furthermore, anthracycline-based regimens are increasingly being
used as adjuvant and/or neoadjuvant chemotherapy for early breast
cancer, and anthracylines therefore have a limited role as salvage
treatment in patients previously exposed in these settings. There
is therefore a clear need to develop new, non-anthracycline-based
regimens that are active in patients failing to respond to anthracy-
clines or who can no longer receive them.
With these considerations, we initiated this phase I study,
aiming to deﬁne the safety proﬁle and to determine the maximum
tolerated dose, the dose-limiting toxicity, and the recommended
dose of docetaxel in combination with cyclophosphamide, without
colony-stimulating factors, as ﬁrst-line chemotherapy in patients
with metastatic breast cancer.
The study establishes a recommended dose of docetaxel
75 mg m
72 in combination with cyclophosphamide 600 mg m
72
given every 3 weeks, without the support of prophylactic rHuG-
CSF, for phase II evaluation in patients with previously untreated
metastatic breast cancer. The maximum tolerated dose was reached
at the dose level combining docetaxel 85 mg m
72 and cyclopho-
sphamide 600 mg m
72, the dose-limiting toxicity being febrile
neutropenia.
The ﬁnding that febrile neutropenia was the dose-limiting toxi-
city of docetaxel with cyclophosphamide is in agreement with an
earlier dose-ﬁnding study evaluating this combination in patients
with various advanced solid tumour types, including patients with
metastatic breast cancer (Valero, 1997). There were, however,
signiﬁcant differences in study design between this and the earlier
study. In contrast with our study, both previously treated and
untreated patients were eligible for the earlier study and dose esca-
lation of both agents was planned.
The starting dose was identical in this and the earlier advanced
solid tumour study (Valero, 1997) and in both the combination of
docetaxel 75 mg m
72 and cyclophosphamide 600 mg m
72 was
well tolerated. Interestingly, further dose escalation was feasible
in the earlier study, to docetaxel 75 mg m
72 and cyclophospha-
mide 700 mg m
72 for previously treated patients and to
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Table 6 Best overall tumour response to treatment (evaluable popula-
tion)
Dose level
I II III
Total
(n=6) (n=7) (n=13) (n=26)
Best overall response
Complete response 0 0 1 1 (3.8%)
Partial response 3 1 5 9 (38%)
No change 3 2 5 10 (38%)
Disease progression 0 2 2 4 (15%)
Objective tumour response
Overall 3 1 6 10 (42.3%)
a
By disease site:
b
Visceral 1/3 2/3 2/6 45/12 (42%)
Liver 1/1 – 1/4 12 (40.0%)
Bone 3/4 1/4 3/4 2/5 (58.3%)
7/12
a95% conﬁdence interval 21.9–61.4%.
bData are number of objective tumour
responses/number of evaluable patients with visceral, liver, or bone disease site
involvement, as appropriate.
Table 7 Pharmacokinetics of docetaxel in combination with cyclophosphamide. Data are expressed as mean+standard deviation
Dose level
I II III Total
(n=5) (n=6) (n=9) (n=20)
Cmax
1 (mgm l
71) 2.10+0.35 2.43+0.70 3.02+0.82 –
AUC[0-?]( mghm l
71) 3.49+1.45 3.44+1.26 4.05+1.22 –
CL (L h m
72) 18.8+6.1 24.3+8.8 22.5+6.2 22.1+7.0
Vss (L m
72)7 6 +66 105+79 94+145 93+108
t½z (h) 10.7+8.8 13.2+11.4 11.4+13.4 11.8+11.3
aPredicted concentration at the end of intravenous infusion. Cmax=maximum plasma concentration; AUC[0-?]=area under the plasma concentration-time curve; CL=total
body clearance; Vss=volume of distribution at steady state; t½z=terminal elimination half-life.
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72 and 800 mg m
72 for previously untreated
patients. The protocol for our study scheduled further dose escala-
tion, of both docetaxel (85–100 mg m
72) and cyclophosphamide
(600–1800 mg m
72), supported by rHuG-CSF (lenograstim
150 mgm
72 day
71 from day 2 until neutrophil recovery, deﬁned
as neutrophil count 51.0610
9 l
71), should the dose-limiting toxi-
city be neutropenia or its complications. Since the dose-limiting
toxicity in the initial part of the study was febrile neutropenia, this
second-step dose escalation was undertaken (Chollet et al, 1998). A
preliminary evaluation showed that the use of lenograstim enabled
substantial increases in the doses of both agents: the maxi-
mum tolerated dose was not reached even at the dose level of doce-
taxel 100 mg m
72 in combination with cyclophosphamide
1200 mg m
72. Recent studies conducted by the National Surgical
Adjuvant Breast and Bowel Project–B-22 (Fisher et al, 1997) and
B-25 (Fisher et al, 1999) – showed no beneﬁt in terms of
disease-free or overall survival of increasing the dose intensity
and the cumulative dose of cyclophosphamide (with or without
rHuG-CSF support) over the standard dose of 600 mg m
72 in
early breast cancer patients receiving combination doxorubicin
and cyclophosphamide chemotherapy. For this reason, we decided
to discontinue the study, stopping further escalation to doce-
taxel 100 mg m
72 in combination with cyclophosphamide
1500 mg m
72 or 1800 mg m
72.
Febrile neutropenia was the only dose-limiting toxicity in this
and the earlier advanced solid tumour study (Valero, 1997).
Neutropenia and its complications are also dose-limiting in
combination chemotherapy with paclitaxel and cyclophosphamide
for advanced or metastatic breast cancer (Kennedy et al, 1996;
Pagani et al, 1997). However, with the paclitaxel and cyclopho-
sphamide combination, severe thrombocytopenia and non-
haematological toxicity are also reported as dose limiting toxicities.
In patients with advanced breast cancer previously treated with no
more than one chemotherapy regimen, dose-limiting toxicities of
febrile neutropenia and severe thrombocytopenia deﬁned a maxi-
mum tolerated dose of paclitaxel 200 mg m
72 with
cyclophosphamide 2000 mg m
72 with or without rHuG-CSF
prophylaxis (Schrijvers et al, 1993). For anthracycline-resistant
metastatic breast cancer, even with rHuG-CSF prophylaxis, dose-
limiting toxicities including myelosuppression, neuropathy, myal-
gia, and typhilitis deﬁned the maximum tolerated dose of
paclitaxel 200 mg m
72 with cyclophosphamide 1250 mg m
72
(Kennedy et al, 1996). Interestingly, in the dose escalation with
lenograstim conducted following this study, no dose-limiting toxi-
city was observed even at the highest administered dose level of
docetaxel 100 mg m
72 in combination with cyclophosphamide
1200 mg m
72.
Fluid retention, a frequent adverse event described in early
studies of docetaxel (Van Oosterom and Schrijvers, 1995; Schrijvers
et al, 1993) occurred in one-half of all patients in this study, but
was never severe. The reduced incidence and severity of docetax-
el-related ﬂuid retention in this and other recent studies is
probably due to the routine administration of a 3-day corticoster-
oid premedication regimen (Riva et al, 1997).
Docetaxel 60 mg m
72 was chosen as the starting dose in this
study on the basis of its antitumour activity and tolerability as a
single agent (Adachi et al, 1996). It was therefore not surprising
that antitumour activity was observed at each docetaxel and cyclo-
phosphamide dose level, and at all disease sites. The overall tumour
response rate was rather lower than that achieved in the earlier
advanced solid tumour study (42 versus 69%). However, it should
be considered that since this was a phase I study, efﬁcacy assess-
ment was not a primary end-point. Only one-quarter of patients
had evaluable disease, and one-half had bone metastases, which
are difﬁcult to assess. Moreover, due to the small study size, the
CI around the response rate of 42% was wide. Phase II studies
are needed and planned to further explore the efﬁcacy of the
recommended dose of docetaxel 75 mg m
72 and cyclophospha-
mide 600 mg m
72.
Although this study deﬁned the recommended dose of docetaxel
in combination with cyclophosphamide for phase II studies as
75 mg m
72, it is of note that the docetaxel 85 mg m
72 dose level
was reasonably well tolerated, despite the incidence of dose-limit-
ing febrile neutropenia. Among 13 patients treated at this dose
level, there were no deaths and the median relative dose intensity
of the combination approached 1. This dose level was the most
active (50% overall tumour response rate), and could be consid-
ered for further evaluation.
The pharmacokinetics of docetaxel did not appear to be inﬂu-
enced by cyclophosphamide when the two drugs were given as
combination chemotherapy, as compared with historical data from
studies of docetaxel monotherapy. All parameters were in agree-
ment with those in two phase I studies in which single-agent
docetaxel was administered as a 1- to 2-h intravenous infusion at
doses ranging from 20–115 mg m
72 (Bruno et al, 1996). Total
body clearance in our study was relatively stable over the three
dose levels tested and almost identical to that for single-agent doce-
taxel (22.1 versus 21.0 l h m
72). Interpatient variability in Vss and
t½z values was marked, but overall mean values were similar to
those described for single-agent docetaxel (Vss=93 versus
67 l m
72;t ½z=12 versus 11 h). Docetaxel and cyclophosphamide
can therefore be administered together without any relevant drug
interaction according to this administration schedule.
In conclusion, docetaxel in combination with cyclophosphamide
is a well tolerated and active combination for ﬁrst-line chemother-
apy of metastatic breast cancer. With the increasing use of
anthracycline-based chemotherapy as adjuvant therapy for meta-
static breast cancer, patients are frequently exposed to high
cumulative doses of anthracyclines and are therefore at risk of
resistance and cardiotoxicity. The combination of docetaxel with
cyclophosphamide, or other non-anthracycline chemotherapeutic
agents, may be particularly useful in patients previously treated
with anthracycline-based chemotherapy but naı ¨ve to the non-
anthracycline agents. However, it must be noted that although
combination chemotherapy is generally associated with higher
response rates in solid tumour oncology, there is no clear evidence
for a survival beneﬁt over the administration of single agents in
metastatic breast cancer. Moreover, because combination
chemotherapy is invariably associated with more toxicity, consid-
eration must be given to the fact that the primary aim of
treatment in this situation is palliation. A phase II study utilising
the recommended dose of docetaxel 75 mg m
72 and cyclopho-
sphamide 600 mg m
72 will further explore the activity and
conﬁrm the safety of the combination.
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